Responses
Clinical/translational cancer immunotherapy
Original research
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
